Black checkmark with a sparkle and a curved line underneath on a white background.
Company

Catheter Precision, Inc.

Ticker
VTAK
Sector
Industry
Report date
November 16, 2026
Valye AI Score

100

Very high visibility
Recent developments
Recent developments summary

Recent news highlights Catheter Precision's financing activities, acquisitions, regulatory approvals, and financial results, alongside broader market news.

Recent developments:
  • Catheter Precision secured $88 million financing to support growth in aviation and medical segments, with stock reacting negatively to the announcement [N13].
  • The company acquired Fly Flyte, Inc., expanding into private aviation services [N13].
  • LockeT wound closure device received UK approval and CE Mark, expanding European market opportunities [N14].
  • Catheter Precision launched a joint venture, Kardionav, for advancements in ventricular tachycardia ablation technology [N15].
  • The company reported Q3 2024 financial results, indicating ongoing operational updates [N18].
Overview

Catheter Precision, Inc. operates in two primary segments: medical devices and private aviation services. The medical device segment includes products such as the LockeT wound closure device, which has received regulatory approvals in the UK and Europe, and ventricular tachycardia ablation technology developed through joint ventures and acquisitions. The aviation segment operates under Fly Flyte, Inc. (FLYTE), providing private aviation services in a competitive and regulated environment. The company has engaged in multiple financing activities, including issuance of convertible preferred stock and warrants, and has related party transactions with extended debt maturities. Financial results indicate ongoing net losses and liquidity constraints as of the latest quarterly period.

Executive summary

Catheter Precision, Inc. is a medical device and private aviation services company with operations disclosed in SEC filings and recent news. The company has engaged in acquisitions, including Fly Flyte, Inc. (FLYTE) for private aviation and Cardionomix, Inc. for cardiac therapy assets. Financial disclosures as of September 30, 2026, show net losses and limited revenue, with liquidity ratios indicating current liabilities exceed current assets. The company faces risks related to the competitive aviation market, regulatory compliance, dilution from convertible securities, and operational challenges in both medical and aviation segments. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.

Scenarios for VTAK

Bull case model:

The company has expanded its medical device portfolio through acquisitions and joint ventures, including advanced cardiac therapy technologies and regulatory approvals for its LockeT device in Europe and the UK. The acquisition of Fly Flyte, Inc. adds a private aviation services segment with growth potential. Recent financing activities provide capital to support growth initiatives. The company's ability to leverage its medical device innovations alongside aviation services could create diversified revenue streams.

Bear case model:

Catheter Precision faces significant financial losses and liquidity challenges, with current liabilities exceeding current assets and ongoing net losses reported. The aviation segment operates in a highly competitive market with risks from economic sensitivity, pilot labor shortages, fuel cost volatility, and regulatory compliance. Dilution risks from convertible preferred stock and warrants may adversely affect existing shareholders. The company also faces operational risks related to integration of acquisitions and regulatory hurdles in both business segments.

Moat:

Catheter Precision's moat is derived from its specialized medical device technologies with regulatory approvals in key markets and its strategic acquisitions expanding its product portfolio in cardiac therapies. The aviation segment's moat is limited due to high competition and reliance on third-party operators. The company's intellectual property rights, regulatory clearances, and joint ventures contribute to differentiation in the medical device market, while the aviation business faces typical industry challenges without significant barriers to entry.

Risks overview
Risks summary
Liquidity constraints combined with operational risks in both medical device and aviation segments, alongside dilution risks from convertible securities, represent the primary challenges for Catheter Precision.
Risks details:

• Liquidity and Financial Risk: As of September 30, 2026, the company reported a current ratio of 0.54 and net losses, indicating liquidity constraints and ongoing need for capital to fund operations [S2].
• Aviation Industry Risks: The Fly Flyte aviation business is exposed to risks including economic sensitivity, competition, reliance on third-party operators, pilot labor market constraints, fuel price volatility, insurance coverage challenges, and regulatory compliance [S2].
• Dilution Risk: The issuance and potential conversion of multiple series of convertible preferred stock and warrants could result in substantial dilution to existing common stockholders [S2].
• Regulatory and Operational Risks: Medical device regulatory approvals and compliance are critical; delays or failures could impact market opportunities. Aviation operations are subject to extensive regulation and operational risks including safety incidents and labor disputes [S1][S2].
• Related Party Transactions: The company has significant related party notes payable and warrants issued to related parties, which may present conflicts of interest and financial risks [S1].

FINAL FORECAST FOR VTAK

Final take one line
Catheter Precision, Inc. exhibits very high visibility with detailed disclosures on its medical device and aviation businesses, financials, and risks.
Final take 12 to 24 month view

Business trends: Expansion through acquisitions and regulatory approvals in medical devices alongside growth in private aviation services.
Execution milestones: Completion of financing rounds, regulatory clearances for LockeT device, and integration of Fly Flyte acquisition.
Key risks: Liquidity constraints, dilution from convertible securities, competitive and regulatory challenges in aviation, and operational risks in medical device commercialization.

Valye AI Visibility Research Score

Very high visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

100
LLM visibility overview
LLM Visibility known facts
  • Catheter Precision, Inc. is a publicly traded company on NYSE American under ticker VTAK [S1].
  • As of March 20, 2026, the company had 2,692,473 shares of common stock outstanding [S1].
  • The company completed a merger in January 2023 acquiring Catheter Precision, Inc. (Old Catheter) and entered into related debt settlement agreements with related parties [S1].
  • The company issued Series J Convertible Preferred Stock in exchange for royalty rights related to its LockeT device, convertible at $1.56 per share subject to stockholder approval [S1].
  • The company has related party notes payable with extended maturity dates and issued Series M Warrants exercisable upon stockholder approval [S1].
  • Catheter Precision formed Cardionomix, Inc. in 2025 and acquired assets related to a Cardiac Pulmonary Nerve Stimulation System for treatment of acute decompensated heart failure [S1].
  • The company acquired Fly Flyte, Inc. (FLYTE), a private aviation services business, and secured $88 million financing to support aviation and medical growth [N13].
  • FLYTE operates in a highly competitive private aviation market with risks including economic sensitivity, reliance on third-party operators, pilot labor market constraints, fuel cost volatility, regulatory compliance, and insurance coverage challenges [S2].
  • Catheter Precision's LockeT wound closure device received CE Mark approval and UK regulatory approval, expanding market opportunities in Europe [N14].
  • The company has reported net losses, including a net loss of $15.1 million for the quarter ended September 30, 2026, with basic EPS of -$8.16 and diluted EPS of -$7.72 [S2].
  • As of September 30, 2026, the company had cash and cash equivalents of $2.39 million, current assets of $3.82 million, and current liabilities of $7.06 million, resulting in a current ratio of 0.54 and a cash ratio of 1.05 [S2].
  • Revenue reported was $96,000 for the quarter ended September 30, 2024 [S2].
  • The company has risks related to dilution from convertible preferred stock and warrants, which could materially dilute existing common stockholders [S2].
  • Catheter Precision has engaged in acquisitions and joint ventures to expand its medical device offerings, including ventricular tachycardia ablation technology [N15].
  • The company has experienced increased trading activity and has addressed going concern doubts in audit opinions [N16][N17].
Sources
Sources - Context summary

Generated 2026-11-17

Sources - Earning calls
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-04-30 | 10-K/A
  • S2 | 2026-11-16 | 10-Q
Sources - News headlines
  • N1 | 2026-11-17 | www.nasdaq.com | Nvidia's Biggest Jensen Huang Problem Was Hiding in Plain Sight | https://www.nasdaq.com/articles/nvidias-biggest-jensen-huang-problem-was-hiding-plain-sight
  • N2 | 2026-11-17 | www.nasdaq.com | NextSource Materials Inc. Q1 Loss Declines | https://www.nasdaq.com/articles/nextsource-materials-inc-q1-loss-declines
  • N3 | 2026-11-17 | www.nasdaq.com | Largo Inc. Q3 Loss Decreases | https://www.nasdaq.com/articles/largo-inc-q3-loss-decreases
  • N4 | 2026-11-17 | www.nasdaq.com | Australian Market Extends Early Losses In Mid-market | https://www.nasdaq.com/articles/australian-market-extends-early-losses-mid-market-6
  • N5 | 2026-11-17 | www.nasdaq.com | Rocket Lab Hit 100 Launches Faster Than Any Other Commercially Developed Rocket. I'd Buy a Small Stake. | https://www.nasdaq.com/articles/rocket-lab-hit-100-launches-faster-any-other-commercially-developed-rocket-id-buy-small
  • N6 | 2026-11-17 | www.nasdaq.com | Soybeans Closes Lower, Despite Record NOPA Crush | https://www.nasdaq.com/articles/soybeans-closes-lower-despite-record-nopa-crush
  • N7 | 2026-11-17 | www.nasdaq.com | Air Industries Group Reminds Investors of November 18 Special Meeting for Proposed Tenax Merger | https://www.nasdaq.com/articles/air-industries-group-reminds-investors-november-18-special-meeting-proposed-tenax-merger
  • N8 | 2026-11-17 | www.nasdaq.com | Unicycive Therapeutics Announces FDA Acceptance of OLC NDA Resubmission and Third Quarter 2026 Financial Results | https://www.nasdaq.com/articles/unicycive-therapeutics-announces-fda-acceptance-olc-nda-resubmission-and-third-quarter
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine